Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Pregabalin Induced Maculopapular Eruption in an Elderly Male

Author(s): Sumit Jaiswal, Sankha Shubhra Chakrabarti, Tulika Rai, Neeraj Dhameja, Atul Mohan, Vandana Yadav and Upinder Kaur*

Volume 17, Issue 4, 2022

Published on: 27 May, 2022

Page: [393 - 398] Pages: 6

DOI: 10.2174/1574886317666220309143913

Price: $65

Abstract

Background: Pregabalin is used in the treatment of neuropathic pain of various etiologies and as an adjuvant in epilepsy. Blockade of the α2δ subunit of L and N-type Ca-channels is its main mechanism of neurotropic action. Compared to other antiepileptics like phenytoin, valproate and lamotrigine, and other neuropathic pain medications such as amitriptyline and duloxetine, pregabalin has a relatively favorable safety profile and hence is a drug of choice for many geriatricians.

Case Presentation: Here we describe a case of maculopapular rash induced by pregabalin in an older man, which resolved with withdrawal of the offending drug and conservative management.

Conclusion: We have also conducted a literature review of similar cases and highlighted the clinical patterns and management strategies for pregabalin-induced skin rashes.

Keywords: Anticonvulsant, dermatology, idiosyncratic, rash, skin, Pregabalin.

« Previous Next »
Graphical Abstract

[1]
Khazaka M, Laverdière J, Bouchard A, Ferreira V, Mathieu A. Identification of possible causative agents in a polymedicated patient pre-senting with toxic epidermal necrolysis. J Pharm Pract 2021; 34(6): 970-4.
[PMID: 32588724]
[2]
Sahota S, Parry RG, Gentile G. Pregabalin-induced urticarial rash and neutropenia in a renal transplant recipient: A case report. BMC Nephrol 2019; 20(1): 207.
[http://dx.doi.org/10.1186/s12882-019-1401-3] [PMID: 31170935]
[3]
Gómez TE, Moreno LL, Extrmera OAM, Gonzalez JO, Gratacós GAR, Garcia RR. First case of skin allergy to pregabalin with positive patch test reaction. Contact Dermat 2019; 81(1): 78.
[http://dx.doi.org/10.1111/cod.13249] [PMID: 30793330]
[4]
Inoue A, Sawada Y, Ohmori S, et al. Maculopapular type drug eruption caused by pregabalin: A case and literature review. Allergol Int 2016; 65(3): 351-2.
[http://dx.doi.org/10.1016/j.alit.2016.02.006] [PMID: 26976337]
[5]
Bamanikar A, Dhobale S, Lokwani S. Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia. Indian J Pharmacol 2013; 45(5): 522-3.
[http://dx.doi.org/10.4103/0253-7613.117748] [PMID: 24130391]
[6]
Ortega-Camarero MA, Avila R, Prados Castaño M, Piñero M, Quiralte J, Cimbollek S. Challenge-based pregabalin induced urticaria and angioedema. A case report. Allergol Immunopathol (Madr) 2012; 40(5): 323.
[http://dx.doi.org/10.1016/j.aller.2011.09.012] [PMID: 22266144]
[7]
Smith TL, Baldwin A, Cunningham LL Jr, Cook AM. Rash associated with pregabalin use. Ann Pharmacother 2008; 42(12): 1899-902.
[http://dx.doi.org/10.1345/aph.1L305] [PMID: 19001532]
[8]
Verma V, Singh N, Jaggi AS. Pregabalin in neuropathic pain: Evidences and possible mechanisms. Curr Neuropharmacol 2014; 12(1): 44-56.
[http://dx.doi.org/10.2174/1570159X1201140117162802] [PMID: 24533015]
[9]
Frampton JE. Pregabalin: A review of its use in adults with generalized anxiety disorder. CNS Drugs 2014; 28(9): 835-54.
[http://dx.doi.org/10.1007/s40263-014-0192-0] [PMID: 25149863]
[10]
Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr 2006; 6(2): 33-7.
[http://dx.doi.org/10.1111/j.1535-7511.2006.00089.x] [PMID: 16604195]
[11]
Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011; 71(5): 672-83.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03703.x] [PMID: 21480947]

Rights & Permissions Print Cite
Article Metrics
36
1
© 2024 Bentham Science Publishers | Privacy Policy